Video

Adam Simmons Outlines Efficacy of ALKS 3831 Across Subgroups of Patients With Schizophrenia

Adam Simmons, director of clinical program management, Alkermes, interviewed at the American Psychiatric Association Annual Meeting, discussed the efficacy of the investigational drug ALKS 3831 (olanzapine/samidorphan) in various patient populations.

Adam Simmons, director of clinical program management, Alkermes, interviewed at the American Psychiatric Association Annual Meeting, discussed the efficacy of the investigational drug ALKS 3831 (olanzapine/samidorphan) in various patient populations.

Transcript

What can the data presented at APA tell us about the effectiveness of ALKS 3831 compared with olanzapine across subgroups of patients?

In the data that we’re presenting here at the APA conference, what it is that we’ve shown is that the antipsychotic efficacy of olanzapine when combined with samidorphan is very similar across 3 different patient populations. One in patients that were treated in an outpatient basis; one in patients that were treated in an outpatient basis combined with schizophrenia and alcohol use disorder, and the third study we had looked at people who were acutely psychotic having an acute exacerbation of schizophrenia and comparing 3831 to placebo with olanzapine as a comparator. In that third study where we were specifically looking at antipsychotic efficacy, we did look at subgroups. We’re planning on presenting that data and describing it more in a manuscript that’ll be published in the future.

Related Videos
SECO 2025
Brianna Rhue, OD, FAAO
Julie Rodman, OD, MS, FAAO
Nate Lighthizer, OD, FAAO
Mile Brujic, OD, FAAO
Julie Rodman, OD, MS, FAAO
I. Benjamin Gaddie, OD, FAAO
Julie Rodman, OD, MS, FAAO
Screenshot of an interview with Rohan Garje, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo